Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose and Steady State Pharmacokinetics Study of 9cUAB30 in Healthy Volunteers.

Kolesar JM, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH.

Cancer Prev Res (Phila). 2019 Sep 4. pii: canprevres.0310.2019. doi: 10.1158/1940-6207.CAPR-19-0310. [Epub ahead of print]

PMID:
31484659
2.

Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma.

Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:262-279. doi: 10.1200/EDBK_200939. Review.

PMID:
30231359
3.

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.

Gee JR, Saltzstein DR, Kim K, Kolesar J, Huang W, Havighurst TC, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House MG, Parnes HL, Bailey HH.

Cancer Prev Res (Phila). 2017 May;10(5):298-307. doi: 10.1158/1940-6207.CAPR-16-0167. Epub 2017 Mar 21.

4.

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.

Kyriakopoulos CE, Braden AM, Kolesar JM, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB.

Invest New Drugs. 2017 Jun;35(3):290-297. doi: 10.1007/s10637-016-0418-8. Epub 2016 Dec 21.

5.

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH.

Am J Clin Exp Urol. 2016 Sep 20;4(2):17-27. eCollection 2016.

6.

American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.

Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, Wollins DS, Blanke CD.

J Clin Oncol. 2016 May 20;34(15):1803-12. doi: 10.1200/JCO.2016.67.2014. Epub 2016 Apr 11.

PMID:
27069078
7.

Serving the State Through Medical Research.

Bailey HH, Golden RN.

WMJ. 2015 Dec;114(6):274-5. No abstract available.

8.

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Fabian CJ, Kimler BF, Zalles CM, Phillips TA, Metheny T, Petroff BK, Havighurst TC, Kim K, Bailey HH, Heckman-Stoddard BM.

Cancer Prev Res (Phila). 2015 Dec;8(12):1146-55. doi: 10.1158/1940-6207.CAPR-15-0109. Epub 2015 Sep 21.

9.

This Is Africa.

Verlo AR, Bailey HH, Cook MR.

J Spec Oper Med. 2015 Fall;15(3):114-9.

PMID:
26360366
10.

Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.

Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH.

Eur J Cancer Prev. 2016 Jul;25(4):312-20. doi: 10.1097/CEJ.0000000000000189.

PMID:
26313229
11.

Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.

Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP.

Pediatr Blood Cancer. 2015 Oct;62(10):1739-46. doi: 10.1002/pbc.25594. Epub 2015 Jul 7.

PMID:
26153194
12.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.

J Clin Oncol. 2015 Mar 1;33(7):786-809. doi: 10.1200/JCO.2014.59.9746. Epub 2015 Jan 20. Review. No abstract available.

PMID:
25605863
13.

Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population.

Agger WA, Siddiqui D, Lovrich SD, Callister SM, Borgert AJ, Merkitch KW, Mason TC, Baumgardner DJ, Burmester JK, Shukla SK, Welter JD, Stewart KS, Washburn MJ, Bailey HH.

Obstet Gynecol. 2014 Nov;124(5):969-77. doi: 10.1097/AOG.0000000000000470.

14.

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH.

J Oncol Pharm Pract. 2015 Dec;21(6):416-24. doi: 10.1177/1078155214541572. Epub 2014 Jul 1.

15.

Cancer chemoprevention is not a failure.

Adhami VM, Bailey HH, Mukhtar H.

Carcinogenesis. 2014 Sep;35(9):2154-5. doi: 10.1093/carcin/bgu141. Epub 2014 Jun 26. No abstract available.

PMID:
24970761
16.

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.

Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH.

J Oncol Pharm Pract. 2015 Apr;21(2):128-31. doi: 10.1177/1078155214528552. Epub 2014 Mar 17.

17.

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.

Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR.

Invest New Drugs. 2014 Apr;32(2):323-9. doi: 10.1007/s10637-013-0035-8. Epub 2013 Oct 10.

18.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH.

Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10.

19.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR.

Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7. doi: 10.1007/s00280-013-2242-6. Epub 2013 Aug 1.

20.

Green tea polyphenols and cancer chemoprevention of genitourinary cancer.

Bailey HH, Mukhtar H.

Am Soc Clin Oncol Educ Book. 2013:92-6. doi: 10.1200/EdBook_AM.2013.33.92. Review.

21.

Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care?

Rocque GB, Barnett AE, Illig LC, Eickhoff JC, Bailey HH, Campbell TC, Stewart JA, Cleary JF.

J Oncol Pract. 2013 Jan;9(1):51-4. doi: 10.1200/JOP.2012.000698.

22.

Predictors of willingness to participate in window-of-opportunity breast trials.

Wisinski KB, Faerber A, Wagner S, Havighurst TC, McElroy JA, Kim K, Bailey HH.

Clin Med Res. 2013 Sep;11(3):107-12. doi: 10.3121/cmr.2013.1136. Epub 2013 Apr 11.

23.

A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.

Kreul SM, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, Borich A, Verma A, Bailey HH.

Cancer Prev Res (Phila). 2012 Dec;5(12):1368-74. doi: 10.1158/1940-6207.CAPR-12-0233. Epub 2012 Oct 11.

24.

Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.

Kenkre VP, Long WL, Eickhoff JC, Blank JH, McFarland TA, Bottner W, Rezazedeh H, Werndli JE, Bailey HH, Kahl BS.

Leuk Lymphoma. 2011 Sep;52(9):1675-80. doi: 10.3109/10428194.2011.580404.

25.

Enhancing the bioavailability of resveratrol by combining it with piperine.

Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, Ahmad N.

Mol Nutr Food Res. 2011 Aug;55(8):1169-76. doi: 10.1002/mnfr.201100117. Epub 2011 Jun 29.

26.

AIDS-related Kaposi's sarcoma of the gastrointestinal tract.

Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR.

J Clin Oncol. 2010 Jun 1;28(16):e250-1. doi: 10.1200/JCO.2009.26.5868. Epub 2010 May 3. No abstract available.

PMID:
20439636
27.

Metastatic soft tissue sarcoma diagnosed by small bowel video capsule endoscopy.

Weiss JM, Attia S, Bailey HH, Weber S, Hu J, Reichelderfer M, Gopal DV.

J Clin Oncol. 2010 May 20;28(15):e233-5. doi: 10.1200/JCO.2009.25.9143. Epub 2010 Apr 5. No abstract available.

28.

A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.

Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE, Hamielec M, Pomplun M, Sharata HH, Puchalsky D, Berg ER, Havighurst TC, Carbone PP.

Cancer Prev Res (Phila). 2010 Jan;3(1):35-47. doi: 10.1158/1940-6207.CAPR-09-0096.

29.

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.

Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH.

Invest New Drugs. 2011 Apr;29(2):316-22. doi: 10.1007/s10637-009-9364-z. Epub 2009 Dec 9.

30.

Green tea polyphenols for prostate cancer chemoprevention: a translational perspective.

Johnson JJ, Bailey HH, Mukhtar H.

Phytomedicine. 2010 Jan;17(1):3-13. doi: 10.1016/j.phymed.2009.09.011. Review.

31.

Brief report: Measuring the attitudes of health care professionals in Dane County toward adolescent immunization with HPV vaccine.

Jensen ME, Hartenbach E, McElroy JA, Faerber A, Havighurst T, Kim KM, Bailey HH.

WMJ. 2009 Jul;108(4):203-5.

32.

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.

Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G.

Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51. doi: 10.1007/s00280-008-0844-1. Epub 2008 Oct 8.

33.

Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.

Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS.

Hematol Oncol. 2009 Mar;27(1):11-6. doi: 10.1002/hon.870.

34.

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.

Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA.

Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57. Epub 2007 Sep 21.

PMID:
17885756
35.

Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.

Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G.

Clin Cancer Res. 2007 Jun 15;13(12):3623-9. Epub 2007 May 17.

36.

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.

Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM; Wisconsin Oncology Network.

Gynecol Oncol. 2007 May;105(2):358-64. Epub 2007 Jan 29.

PMID:
17258800
37.

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.

Bailey HH, Mahoney MR, Ettinger DS, Maples WJ, Fracasso PM, Traynor AM, Erlichman C, Okuno SH.

Cancer. 2006 Nov 15;107(10):2462-7.

38.

Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.

Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH; Wisconsin Oncology Network.

Ann Oncol. 2006 Sep;17(9):1418-23. Epub 2006 Jun 9.

PMID:
16766582
39.

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.

Armstrong DK, Fleming GF, Markman M, Bailey HH.

Gynecol Oncol. 2006 Nov;103(2):391-6. Epub 2006 Apr 19.

PMID:
16626792
40.
41.

Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.

Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A.

Cancer Invest. 2005;23(1):13-8.

PMID:
15779863
42.

Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125.

Allen GW, Forouzannia A, Bailey HH, Howard SP.

Gynecol Oncol. 2004 Sep;94(3):811-3.

PMID:
15350377
43.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.

Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76. Epub 2004 Jun 15.

PMID:
15205914
44.

Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.

Liu G, Wilding G, Staab MJ, Horvath D, Miller K, Dresen A, Alberti D, Arzoomanian R, Chappell R, Bailey HH.

Clin Cancer Res. 2003 Sep 15;9(11):4077-83.

45.

Gemcitabine, Paclitaxel, and piritrexim: a phase I study.

Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP.

Am J Clin Oncol. 2003 Jun;26(3):280-4.

PMID:
12796601
46.

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.

Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G.

Cancer Chemother Pharmacol. 2002 Dec;50(6):465-72. Epub 2002 Oct 2.

PMID:
12451473
47.

Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.

Hartenbach EM, Becker JM, Grosen EA, Bailey HH, Petereit DG, Laxova R, Schink JC.

Genet Test. 2002 Summer;6(2):75-8.

PMID:
12229876
48.

A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S.

Gynecol Oncol. 2002 Jun;85(3):464-8.

PMID:
12051875
49.

Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.

Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP.

J Pediatr Hematol Oncol. 2001 Nov;23(8):500-5.

PMID:
11878777
50.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH.

Clin Cancer Res. 2000 Feb;6(2):390-6.

Supplemental Content

Loading ...
Support Center